Citicoline Should Not Be Used in Acute Ischemic Stroke
Citicoline is not recommended for the treatment of acute ischemic stroke at any time point and should not be administered, as the American Heart Association/American Stroke Association issues a Grade A (strong) recommendation against its use based on definitive evidence showing no clinical benefit. 1, 2
Why Citicoline Is Not Recommended
The evidence against citicoline is conclusive and based on the highest quality data:
The International Citicoline Trial on Acute Stroke (ICTUS), the definitive large-scale European multicenter randomized controlled trial enrolling 2,298 patients with moderate-to-severe ischemic stroke, demonstrated no difference in 90-day global outcomes between citicoline and placebo (odds ratio 1.03; 95% CI 0.86-1.25; p=0.364). 1, 2
This large, well-designed trial definitively refutes earlier smaller studies and pooled analyses that suggested potential benefit when started within 24 hours. 2, 3
The American Heart Association/American Stroke Association explicitly states that no agent with putative neuroprotective effects, including citicoline, can be recommended for acute ischemic stroke treatment. 1, 4
Critical Pitfall to Avoid
Do not be misled by older positive studies or meta-analyses. 2 While earlier pooled analyses suggested modest benefit (≈25% recovery vs ≈20% with placebo when started within 24 hours) 3, and some meta-analyses showed statistical significance 5, the definitive ICTUS trial with 2,298 participants provides the strongest evidence that citicoline offers no clinical benefit. 2 Relying on this unproven agent diverts resources and attention from evidence-based therapies that actually improve outcomes. 2
What You Should Use Instead
Focus on proven interventions that reduce mortality and disability:
Acute Reperfusion Therapy
- Intravenous alteplase (rtPA) within 3-4.5 hours of symptom onset for eligible patients. 2, 4
- Endovascular thrombectomy within guideline-specified time windows for large-vessel occlusions. 2, 4
Early Antiplatelet Therapy
- Aspirin 160-325 mg orally within 24-48 hours after stroke onset for patients not receiving thrombolysis, after excluding intracranial hemorrhage. 2, 4
- Do not administer aspirin within 24 hours of thrombolytic therapy. 6
Blood Pressure Management
- Maintain systolic/diastolic pressure <180/105 mmHg for 24 hours after reperfusion therapy to reduce hemorrhagic risk. 2, 4
- For patients not receiving reperfusion, only lower blood pressure if extremely elevated (>220/120 mmHg), with modest 10-15% reduction. 4
Specialized Care
- Admission to a dedicated stroke unit with coordinated interdisciplinary care improves outcomes. 1, 2, 4
The Bottom Line
There is no duration for which citicoline should be administered because it should not be used at all in acute ischemic stroke. 1, 2 The question of "until when" is moot—the drug lacks efficacy despite adequate safety profile. 1 Time and resources should be directed toward rapid assessment, imaging, and administration of proven therapies rather than unproven neuroprotective agents. 4